Literature DB >> 30104240

Actin Cytoskeleton Remodeling Drives Breast Cancer Cell Escape from Natural Killer-Mediated Cytotoxicity.

Hannah Wurzer1,2, Coralie Guerin3,4, Antoun Al Absi1,5, Celine Hoffmann1, Flora Moreau1, Xianqing Mao1, Joshua Brown-Clay1, Rémi Petrolli1, Carla Pou Casellas1, Monika Dieterle6, Jean-Paul Thiery7,8, Salem Chouaib7,9, Guy Berchem1, Bassam Janji1, Clément Thomas10.   

Abstract

Elucidation of the underlying molecular mechanisms of immune evasion in cancer is critical for the development of immunotherapies aimed to restore and stimulate effective antitumor immunity. Here, we evaluate the role of the actin cytoskeleton in breast cancer cell resistance to cytotoxic natural killer (NK) cells. A significant fraction of breast cancer cells responded to NK-cell attack via a surprisingly rapid and massive accumulation of F-actin near the immunologic synapse, a process we termed "actin response." Live-cell imaging provided direct evidence that the actin response is associated with tumor cell resistance to NK-cell-mediated cell death. High-throughput imaging flow cytometry analyses showed that breast cancer cell lines highly resistant to NK cells were significantly enriched in actin response-competent cells as compared with susceptible cell lines. The actin response was not associated with a defect in NK-cell activation but correlated with reduced intracellular levels of the cytotoxic protease granzyme B and a lower rate of apoptosis in target cells. Inhibition of the actin response by knocking down CDC42 or N-WASP led to a significant increase in granzyme B levels in target cells and was sufficient to convert resistant breast cancer cell lines into a highly susceptible phenotype. The actin response and its protective effects were fully recapitulated using donor-derived primary NK cells as effector cells. Together, these findings establish the pivotal role of actin remodeling in breast cancer cell resistance to NK-cell-mediated killing.Significance: These findings establish the pivotal role of the actin cytoskeleton in driving breast cancer cell resistance to natural killer cells, a subset of cytotoxic lymphocytes with important roles in innate antitumor immunity. Cancer Res; 78(19); 5631-43. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30104240     DOI: 10.1158/0008-5472.CAN-18-0441

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

1.  Placental-Cadherin, a biomarker for local immune status and poor prognosis among patients with tongue squamous cell carcinoma.

Authors:  Haixia Wang; Tianliang Yu; Limin Mao
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-11-26       Impact factor: 2.503

Review 2.  Clinical and Biological Aspects of Disseminated Tumor Cells and Dormancy in Breast Cancer.

Authors:  Alexander Ring; Maria Spataro; Andreas Wicki; Nicola Aceto
Journal:  Front Cell Dev Biol       Date:  2022-06-28

Review 3.  Exploring clinical implications and role of non-coding RNAs in lung carcinogenesis.

Authors:  Swagata Roy; Neeldeep Ganguly; Satarupa Banerjee
Journal:  Mol Biol Rep       Date:  2022-01-25       Impact factor: 2.742

4.  Methodology to analyze gene expression patterns of early mammary development in pig models.

Authors:  Matthew A Moss; Breanne Williams; Farzana Ferdous; Tom Scott; Heather W Dunn
Journal:  Mol Biol Rep       Date:  2020-03-26       Impact factor: 2.316

5.  Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be Overcome In Vitro by Pharmacological Inhibition of Cdc42-Induced Actin Cytoskeleton Remodeling.

Authors:  Hannah Wurzer; Liza Filali; Céline Hoffmann; Max Krecke; Andrea Michela Biolato; Jérôme Mastio; Sigrid De Wilde; Jean Hugues François; Anne Largeot; Guy Berchem; Jérôme Paggetti; Etienne Moussay; Clément Thomas
Journal:  Front Immunol       Date:  2021-05-24       Impact factor: 7.561

6.  Dysregulation of circulating CDC42 and its correlation with demographic characteristics, comorbidities, tumor features, chemotherapeutic regimen and survival profile in non-small-cell lung cancer patients.

Authors:  Jie Yan; Daihong Wan
Journal:  J Clin Lab Anal       Date:  2021-12-24       Impact factor: 2.352

Review 7.  Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer.

Authors:  Molly A Nelson; Worapol Ngamcherdtrakul; Shiuh-Wen Luoh; Wassana Yantasee
Journal:  Cancer Metastasis Rev       Date:  2021-05-07       Impact factor: 9.237

Review 8.  The regulatory function of mixed lineage kinase 3 in tumor and host immunity.

Authors:  Sandeep Kumar; Sunil Kumar Singh; Basabi Rana; Ajay Rana
Journal:  Pharmacol Ther       Date:  2020-10-09       Impact factor: 13.400

Review 9.  Focus on Cdc42 in Breast Cancer: New Insights, Target Therapy Development and Non-Coding RNAs.

Authors:  Yu Zhang; Jun Li; Xing-Ning Lai; Xue-Qiao Jiao; Jun-Ping Xiong; Li-Xia Xiong
Journal:  Cells       Date:  2019-02-11       Impact factor: 6.600

10.  Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia.

Authors:  Sabrina Kraus; Martin K Kortüm; Andoni Garitano-Trojaola; Ana Sancho; Ralph Götz; Patrick Eiring; Susanne Walz; Hardikkumar Jetani; Jesus Gil-Pulido; Matteo Claudio Da Via; Eva Teufel; Nadine Rhodes; Larissa Haertle; Estibaliz Arellano-Viera; Raoul Tibes; Andreas Rosenwald; Leo Rasche; Michael Hudecek; Markus Sauer; Jürgen Groll; Hermann Einsele
Journal:  Commun Biol       Date:  2021-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.